TROPOSplice Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction
- Coordinator
- Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (f.s.p.), Spain
- Runs
- 1 February 2027 to 31 January 2032
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101300314
What the project is doing
In the project's own words, from its summary on CORDIS.
Diastolic dysfunction, i.e. impaired cardiac relaxation and filling, is a hallmark shared by various heart diseases, including hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF). It is often driven by excessive calcium sensitivity of the cardiac myofilaments, and in HCM and HFpEF alike, is associated with disrupted adrenergic signalling, culminating in reduced responsiveness of the heart to adrenaline.
In the healthy heart, adrenergic stimulation normally decreases myofilament calcium sensitivity via phosphorylation of the N-terminus of cardiac troponin I (cTnI). Remarkably, this effect can also be mimicked by truncation of the cTnI N-terminus. We recently discovered that small mammals such as bats and shrews, which have extraordinarily high cardiac demands, have evolved to skip the exon encoding the cTnI N-terminus via alternative splicing or genomic deletion.
This creates a permanently desensitized cTnI, bypassing the need for sustained β-adrenergic signalling. While alternative splicing of cTnI does not naturally occur in humans or most other mammals, it could be therapeutically induced using antisense oligonucleotides (AONs) in order to increase myocardial relaxation rate. TROPOSplice aims to develop a splice-switching antisense therapeutic that induces cTnI exon 3 skipping to mimic the myofilament desensitizing effect of adrenaline, leveraging a bioinspired strategy “from bats to bedside”.
Crucially, as this approach acts downstream of adrenergic receptors, it is compatible with mainstay cardiovascular treatments such as beta-blockers. We will adopt a translational approach, from cultured cardiomyocytes to in vivo mouse models, to optimise AON design and delivery and to investigate the physiological effects of induced cTnI exon 3 skipping. This project offers a novel, evolution-guided therapeutic strategy to treat diastolic dysfunction and could ultimately benefit patients with HCM, HFpEF, and related heart conditions.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (f.s.p.) | Madrid | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI